Overview First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors Status: Not yet recruiting Trial end date: 2027-07-11 Target enrollment: Participant gender: Summary This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors. Phase: Phase 1/Phase 2 Details Lead Sponsor: Daiichi Sankyo, Inc.